Biomarker data quality is of the utmost importance for confident decision making, particularly when working with complex and dynamic metabolomics measures. With a high complexity CLIA-certified, CAP-accredited clinical laboratory, Sapient upholds stringent standards for testing accuracy and results reliability.
Ensuring robust discovery
Our projects typically begin in our R&D lab with nontargeted discovery screenings using Sapient’s high throughput rLC-MS systems, which broadly capture thousands of small molecule biomarkers per sample, from very polar to very nonpolar molecules.
Potential for discovery is highly dependent on these systems delivering reproducible measures with limited technical variance, and we perform rigorous quality control with real-time monitoring of over 50 parameters related to rLC-MS function, data quality, and sample integrity.
CLIA-certified, CAP-accredited laboratory
Once we have identified and validated a key biomarker of interest, we can use our clinical lab to translate it into a targeted assay for use in a clinical setting, including for clinical trials. Sapient’s clinical lab is certified as a high complexity CLIA lab, developing and performing advanced biomarker assays that adhere to the most stringent CLIA regulations.
Sapient is also CAP-accredited, having passed an in-depth inspection by the College of American Pathologists of our clinical laboratory facilities, equipment, processes, and quality control measures. CAP accreditation confirms we uphold or exceed CLIA standards with exceptional testing proficiency, accuracy, and reliability.